193 related articles for article (PubMed ID: 31803503)
1. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
2. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
3. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.
Joerger M; Schaer-Thuer C; Koeberle D; Matter-Walstra K; Gibbons-Marsico J; Diem S; Thuerlimann B; Cerny T
Eur J Clin Pharmacol; 2014 Jun; 70(6):719-25. PubMed ID: 24609468
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt AM; Walter M; Herbrand AK; Jörger M; Moffa G; Novak U; Hemkens L; Kasenda B
BMJ Open; 2022 May; 12(5):e060453. PubMed ID: 35613810
[TBL] [Abstract][Full Text] [Related]
5. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
Lerose R; Musto P; Aieta M; Papa C; Tartarone A
Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
[TBL] [Abstract][Full Text] [Related]
7. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
8. [Off-label therapy from the perspective of the medical insurance service].
Grell L; Rieger M
Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
[TBL] [Abstract][Full Text] [Related]
9. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
10. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
Messori A; Fadda V; Trippoli S
J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
[TBL] [Abstract][Full Text] [Related]
11. Reimbursement policies constrain the practice of oncology.
Laetz T; Silberman G
JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
[TBL] [Abstract][Full Text] [Related]
12. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
13. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
Janzen RW; Ludwig WD;
Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
[TBL] [Abstract][Full Text] [Related]
14. Value-based payment models in oncology: will they help or hinder patient access to new treatments?
Shah S; Reh G
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP188-SP190. PubMed ID: 28665677
[No Abstract] [Full Text] [Related]
15. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
[TBL] [Abstract][Full Text] [Related]
16. Access to anti-cancer drugs in India: is there a need to revise reimbursement policies?
Haitsma G; Patel H; Gurumurthy P; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):289-296. PubMed ID: 29466887
[TBL] [Abstract][Full Text] [Related]
17. Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011.
Schröder C; Dörks M; Kollhorst B; Blenk T; Dittmann RW; Garbe E; Riedel O
J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):806-813. PubMed ID: 28618239
[TBL] [Abstract][Full Text] [Related]
18. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
[TBL] [Abstract][Full Text] [Related]
19. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience.
Fontanals S; Esteve A; González A; Ibáñez C; Mesía R; Clopés A
Pharmacol Res Perspect; 2024 Feb; 12(1):e1167. PubMed ID: 38193611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]